Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

LATEST
Tencent’s PUBG Mobile Game Hits $3 Billion Milestone
Luckin Coffee Shareholders Vote to Remove Chairman, Bloomberg Reports
France Won’t Ban But Will Discourage Use of Huawei 5G Equipment, Official Says
Trending in China: ‘Lipstick King’ Li Jiaqi Settles in Shanghai, Prompting a Rethink of ‘Talent’
Tencent Plays in U.S. With California Game Studio Launch
Trending in China: Shenzhen Thinks Only Children Should Get Paid Leave to Look After Their Parents - Cue Heated Debate
German Drugmaker BI Launches Shanghai Center to Harness Chinese Expertise
Chinese Self-Driving Truck Firm Aims to Cover Most of U.S. by 2024
Trending in China: Chinese Netizens Tell Indian Prime Minister Modi To ‘Shut The Door On The Way Out’ As He Quits Weibo
Trending in China: If You Can’t Beat Them, Join Them – Why Tencent is Laughing At Itself
Meituan Eyes Robot-Enabled Deliveries with $14 Million Investment in PuduTech
India Ban Could Hit TikTok’s Parent Company to the Tune of $6 Billion
Sina Weibo to Issue $750 Million in Bonds
Embattled Leshi Forced to Sell Smart TV, Livestreaming Trademarks
Autowise.ai and Swiss Cleaning Carmaker Launch Driverless Street Sweeper
Trending in China: How an ‘Old Godmother’ Took on China’s Internet Giant and Won
China’s IT Spending Expected to Hit $297 Billion: IDC
TikTok Moves Data Protection of European Users from U.S. to U.K. and Ireland
Trending in China: Dazed and Confused – China’s Elderly in Online Pandemic World
Alibaba-Owned Taobao Live Sacks Former Operating Head for Corruption
China’s Hansoh Pharma Eyes $1 Billion Hong Kong IPO

By Wei Yiyang and Han Wei / May 31, 2019 05:36 AM / Business & Tech

Photo: VCG

Photo: VCG

Chinese drugmaker Hansoh Pharmaceutical Group plans to raise as much as $1 billion in a Hong Kong initial public offering after securing nine cornerstone investors including Singapore’s sovereign wealth fund GIC and China’s Boyu Capital.

The Jiangsu-based company is offering 551 million shares at HK$13.06 ($1.66) to HK$14.26 apiece, according to terms of the deal seen by Caixin. The offering presents about 9.7% of the company’s total equity after the listing.

Nine cornerstone investors have agreed to buy a combined $344 million of the offering, according to the term sheet. GIC made the biggest commitment of $70 million, followed by Boyu’s $60 million. Other cornerstones include China’s Ally Bridge and Hillhouse Capital Group, Europe-based asset manager Prime Capital and U.S. healthcare investment firm OrbiMed.

Hansoh is set to price the deal June 5 and start trading June 14.

Established in 1995, Hansoh’s products focus on central nervous system diseases, oncology, anti-infectives, diabetes, and gastrointestinal and cardiovascular therapies. In 2018, the company booked 7.7 billion yuan ($1.1 billion) of revenue with net profit of 190 million yuan, according to the prospectus.


Share this article
Open WeChat and scan the QR code